PharmAthene (PIP) to Begin Added Phase II Trial on SparVax, Sees Efficacy at Over 90% Protection
Tweet
Share
E-mailGet Alerts PIP Hot Sheet
Join SI Premium – FREE
PharmAthene, Inc. (Amex: PIP) announced today that Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer, presented a comprehensive update on the Company's novel SparVax™ rPA anthrax vaccine program at the 2012 World Vaccine Congress, held at the Gaylord National Convention Center in Washington, DC, April 11-14, 2012.
SparVax™ is being developed to meet the government's need for an improved second generation anthrax vaccine that is safe, convenient, more cost-effective, and capable of providing rapid manufacturing scale-up in response to a national security emergency.
New data based on a recent analysis of previous human clinical trial immunogenicity data and non-clinical animal study results for SparVax™ suggested a preliminary estimate of efficacy in humans of over 90% protection and nearly 100% protection based on a 6- and 12-month booster dose, respectively. This analysis is based on a correlate of protection established under the Animal Rule in accordance with FDA guidelines.
SparVax™ is being developed to meet the government's need for an improved second generation anthrax vaccine that is safe, convenient, more cost-effective, and capable of providing rapid manufacturing scale-up in response to a national security emergency.
New data based on a recent analysis of previous human clinical trial immunogenicity data and non-clinical animal study results for SparVax™ suggested a preliminary estimate of efficacy in humans of over 90% protection and nearly 100% protection based on a 6- and 12-month booster dose, respectively. This analysis is based on a correlate of protection established under the Animal Rule in accordance with FDA guidelines.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Knorex discloses going concern note in annual report
- Boeing names Ryan Shedd as new SVP and controller
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
Corporate News, Hot Corp. NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
